
    
      It is an open labelled, randomized, mono-center phase III clinical trail.A total of 250
      patients with resected stage IB to stage IIIA non-small cell lung cancer will either the
      group of vinorelbine plus cisplatin plus endostar or the group of vinorelbine plus cisplatin
      randomly. The primary end point was overall survival; principal secondary end points were
      recurrence-free survival and the toxicity and safety of the regimens.The major inclusive
      criteria are pathological confirmed non-small cell lung cancer after complete resection and
      can tolerate chemotherapy safely.The tissue and blood samples will be banked for further
      investigation. All of the enrolled patients will be followed up until death or over 5 years.
    
  